Treatment of Diabetes. (Please refer to the Benefit Schedule for other benefit provisions which may apply.)
Treatment of Diabetes. We cover expenses incurred for the following equipment and supplies for the treatment of diabetes, if recommended or prescribed by a Practitioner, including a nurse practitioner/clinical nurse specialist: blood glucose monitors and blood glucose monitors for the legally blind; test strips for glucose monitors and visual reading and urine testing strips; insulin; injection aids; cartridges for the legally blind; syringes; insulin pumps and appurtenances thereto; insulin infusion devices; and oral agents for controlling blood sugar. \ Coverage under this provision for a short-acting, intermediate acting, rapid acting, long- acting, and pre-mixed insulin product in each category is provided without the application of any deductible, and any copayment or coinsurance for the purchase of such insulin product shall not exceed $35 per 30-day supply. We cover expenses incurred for diabetes self-management education to ensure that Covered Persons with diabetes are educated as to the proper self-management and treatment of their diabetic condition, including information on proper diet. Diabetes self- management education shall be provided by a dietitian registered by a nationally recognized professional association of dietitians, or a health care professional recognized as a Certified Diabetes Educator by the American Association of Diabetes Educators or a registered pharmacist in the State qualified with regard to management education for diabetes by any institution recognized by the board of pharmacy of the State of New Jersey.
Treatment of Diabetes. Subjects who are diabetic at study entry or who become diabetic during the course of the study will be provided with ***. Subjects will be instructed to ***. Diabetic subjects will ***. *** is suggested as the initial therapy for *** type 2 diabetes ***. ***, including ***, should be reserved for subjects who cannot achieve adequate control with other modes of treatment. *** are prohibited, and subjects requiring treatment with these medications must be discontinued from the trial. Subjects with consistently elevated fasting blood glucose values should ***. For this study, actionable levels for glucose values are ***. Subjects who note *** fasting glucose values *** in daily glucose monitoring logs during the week prior to a study visit would be considered appropriate for ***. Subjects whose fasting blood glucose ***, or whose blood glucose cannot be adequately controlled with the concomitant treatments allowed in this trial should be discontinued from study treatment and referred back to their primary healthcare provider for additional glycemic management. Subjects may continue attending study visits ***. During treatment, subjects whose fasting blood glucose is ***. When discontinuing medications, *** should be discontinued first, followed by ***, and finally ***.
Treatment of Diabetes. Subjects who become diabetic during the course of the study will be provided with ***. They will be instructed to ***. Diabetic subjects will ***. Subjects who develop elevated fasting blood glucose values during the study should ***. *** is suggested as the initial therapy for *** type 2 diabetes ***. ***, including ***, should be reserved for subjects who cannot achieve adequate control with other modes of treatment. *** are prohibited, and subjects requiring treatment with these medications must be discontinued from the trial. Subjects whose blood glucose cannot be adequately controlled with the concomitant treatments allowed in this trial should be maintained in the study but discontinued from treatment, and referred back to their primary health care provider for more intensive treatment (see Section 6.4). During treatment, subjects whose fasting blood glucose is ***.
Treatment of Diabetes. Subjects who develop type 2 diabetes during the course of the study will be provided with blood glucose meters and supplies and will be provided appropriate usage instructions. They will be instructed to measure a fasting morning glucose daily and to record the results in the blood glucose and hypoglycemic event log. Diabetic subjects will bring their meters and logs to each visit. If concomitant antidiabetic therapy is determined necessary, metformin is suggested as the initial therapy for newly-emergent type 2 diabetes unless contraindicated in a specific subject. Insulin secretagogues, including SFUs and meglitinides, either alone or in combination with other medications, should be reserved for subjects who cannot achieve adequate control with other modes of treatment. Insulins and incretins are prohibited, and subjects requiring treatment with these medications must be discontinued from the trial. Subjects whose blood glucose cannot be adequately controlled with the concomitant treatments allowed in this trial should be maintained in the study but discontinued from treatment, and referred back to their primary healthcare provider for more intensive treatment (see Section 7.3). During treatment, subjects whose fasting blood glucose is less than 72 mg/dL on 2 or more occasions, or who experience any signs or symptoms associated with hypoglycemia, should have their antidiabetic therapy reevaluated.
